Global Community
Our community narratives are driven by numbers and valuation.
Community Investing Ideas
Global Weekly Picks
Orezone is an emerging gold producer with operations in West Africa (Bomboré) and Canada (Casa Berardi)
Investment Memo – Orezone Gold Corporation Executive Summary Orezone Gold Corporation (“Orezone” or the “Company”) is transitioning into a diversified mid-tier gold producer following the transformational acquisition of Hecla Québec, including the Casa Berardi mine in Canada. This acquisition complements its core Bomboré operation in Burkina Faso and materially increases production scale, reserves, and geographic diversification.Read more
Cosmo Pharmaceuticals Announces Strong Full Year 2024 Revenue and Cash and Provides Business and Pipeline Updates
Catalysts Preliminary Unaudited Revenue and Cash Revenue: €266.8 million, representing a year-on-year increase of 188% compared to €92.8 million in 2023. This includes significant project-based revenues from GI Genius™ and Winlevi® of €190.2 million.Read more
Partners Group Holding will achieve an 8.14% revenue rise over the next 5 years
A continuación tienes un Investment Memo estilo banca de inversión (sell-side / IB pitch) sobre Partners Group Holding AG (PGHN SW) integrando: Insights clave del Capital Markets Day 2026 Conocimiento sectorial tipo Simply Wall St (framework de calidad, crecimiento, riesgos y valoración implícita) Foco específico en riesgos de crédito privado + riesgos macro (recesión/estanflación/geopolítica) Investment Memo – Partners Group Holding AG Resumen Ejecutivo Rating interno: Neutral / Selectivo (Buy en horizonte largo con cautela cíclica) Tesis: Partners Group (“PG”) es una de las plataformas líderes globales en private markets con ~$185bn en AuM y fuerte posicionamiento en soluciones a medida (≈67% del AuM). Su modelo integrado y su disciplina de inversión han generado retornos superiores en múltiples ciclos.Read more
I am a shareholder and my investment thesis is maintained
Paradigm Biopharmaceuticals is testing a long-used drug as an injection that could do more than just mask knee arthritis pain, but the whole story hinges on whether its large late-stage study delivers. Fast-track status adds momentum, yet approval is still a long way off—and setbacks could mean more fundraising and a sharp fall in sentiment.Read more
Future P/E of 15.5x Reflects Jarir's Balanced Growth Expectations
Jarir looks more like a steady, dividend-paying business than a fast grower, with recent results helped by strong phone demand that may not last. If you’re looking for reliable income, the key question is whether today’s price already reflects that stability and payout.Read more
Nevada 1st-Tier 30 Baggers Silver Play Potential
Blackrock Silver is chasing a high-quality silver and gold find in Nevada, with early work suggesting the deposit could be much bigger than the market expects if drilling keeps delivering. But it’s still years away from proving it can become a real mine, and delays, new fundraising, or weaker metal prices could quickly change the story.Read more
The Industrialist of the Skies – Scaling with "Automotive DNA
Archer Aviation bets that air taxis can move from flashy prototypes to real-world production, helped by Stellantis’ car-making know-how and a factory being built to churn out aircraft at scale. The big swing factor is getting regulators to approve its Midnight aircraft, which could turn today’s high-risk story into an actual commercial launch.Read more
